The present invention relates to a consumable product comprising malted oats and/or a leachate of malted oats for use, if consumed in an amount sufficient enough to induce endogenous production of Protein Antisecretory Factor (Protein AF) and/or fragments thereof in a mammal after consumption, in increasing cardiac output and/or decreasing the recovery process of a mammal during and/or after physical activity, thereby treating and/or preventing muscle damage caused by strains and/or tears in an athletic mammal, as well as for preventing paralysis during and/or after physical activity. Said consumption of said consumable product before during and/or after said physical activity has for the first time been found to stabilize the Erythrocyte Fluid Volume fraction (EFV) of a mammal during and/or after physical activity at a value of no more than 3% over resting value, such as at a value between 37-38%, and to stabilize the creatine kinase value of said mammal at a lower value than for mammals not consuming SPC, i.e. at values which indicate reduced muscle stress and damage.
The present invention relates to a consumable product comprising malted oats and/or a leachate of malted oats for use, if consumed in an amount sufficient enough to induce endogenous production of Protein Antisecretory Factor (Protein AF) and/or fragments thereof in a mammal after consumption, in increasing cardiac output and/or decreasing the recovery process of a mammal during and/or after physical activity, thereby treating and/or preventing muscle damage caused by strains and/or tears in an athletic mammal, as well as for preventing paralysis during and/or after physical activity. Said consumption of said consumable product before during and/or after said physical activity has for the first time been found to stabilize the Erythrocyte Fluid Volume fraction (EFV) of a mammal during and/or after physical activity at a value of no more than 3% over resting value, such as at a value between 37-38%, and to stabilize the creatine kinase value of said mammal at a lower value than for mammals not consuming SPC, i.e. at values which indicate reduced muscle stress and damage.
The use of the consumable product is intended as food or feed for humans and/or animals, such as but not limited to horses and dogs.
The present invention relates to a consumable product comprising malted oats and/or a leachate of malted oats for use, if consumed in an amount sufficient enough to induce endogenous production of Protein Antisecretory Factor (Protein AF)and/or fragments thereof in a mammal after consumption, in increasing cardiac output and/or decreasing the recovery process of a mammal during and/or after physical activity, thereby treating and/or preventing muscle damage caused by strains and/or tears in an athletic mammal, as well as for preventing paralysis during and/or after physical activity. Said consumption of said consumable product before during and/or after said physical activity has for the first time been found to stabilize the Erythrocyte Fluid Volume fraction (EFV) of a mammal during and/or after physical activity at a value of no more than 3% over resting value, such as at a value between 37-38%, and to stabilize the creatine kinase value of said mammal at a lower value than for mammals not consuming SPC, i.e. at values which indicate reduced muscle stress and damage. The use of the consumable product is intended as food or feed for humans and/or animals, such as but not limited to horses and dogs.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
The disclosure relates to a consumable product comprising malted dehulled oats and/or a leachate of malted dehulled oat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted dehulled oats comprised in the consumable product disclosed herein is produced by a novel malting process.
The disclosure relates to a consumable product comprising malted dehulled oats and/or a leachate of malted dehulled oat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted dehulled oats comprised in the consumable product disclosed herein is produced by a novel malting process.
The malted dehulled oats and/or a leachate of malted dehulled oats comprised in the consumable product comprises (i) avenanthramide D, wherein the concentration of (i) is higher as compared to the corresponding non-malted dehulled oats, and optionally one or more of the compounds selected from the group consisting of (ii) avenanthramide A, (iii) avenathramide C, (iv) avenanthramide C methyl ester, (v) (Z)-N-feruloyl 5-hydroxyanthranilic acid, (vi) avenanthramide G, and (vii) a compound selected from the group consisting of guaiacol or a derivative thereof, L-tryptophan , DL-phenylalanine, and any combination thereof, wherein the concentration of one or more of (ii-vii) is higher as compared to in the corresponding non-malted dehulled oats.
The disclosure relates to a consumable product comprising malted dehulled oats and/or a leachate of malted dehulled oat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted dehulled oats comprised in the consumable product disclosed herein is produced by a novel malting process.
The malted dehulled oats and/or a leachate of malted dehulled oats comprised in the consumable product comprises (i) avenanthramide D, wherein the concentration of (i) is higher as compared to the corresponding non-malted dehulled oats, and optionally one or more of the compounds selected from the group consisting of (ii) avenanthramide A, (iii) avenathramide C, (iv) avenanthramide C methyl ester, (v) (Z)-N-feruloyl 5-hydroxyanthranilic acid, (vi) avenanthramide G, and (vii) a compound selected from the group consisting of guaiacol or a derivative thereof, L-tryptophan , DL-phenylalanine, and any combination thereof, wherein the concentration of one or more of (ii-vii) is higher as compared to in the corresponding non-malted dehulled oats.
The disclosure further provides use of the consumable product as food or feed for humans and/or animals, as well as for medical use.
The disclosure relates to a consumable product comprising malted wheat and/or a leachate of malted wheat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted wheat of the consumable product comprises (i) 2-methoxyphenol and/or a derivate thereof, and (ii) 2,4-dihydroxy-7-methoxy-(2)-1,4-benzoxazin-3(4H)-one derivative, wherein (a) the concentration of (i) is higher and/or substantially the same as compared to the corresponding non-malted wheat, and (b) the concentration of (ii) is higher as compared to the corresponding non-malted wheat.
The disclosure relates to a consumable product comprising malted wheat and/or a leachate of malted wheat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted wheat of the consumable product comprises (i) 2-methoxyphenol and/or a derivate thereof, and (ii) 2,4-dihydroxy-7-methoxy-(2)-1,4-benzoxazin-3(4H)-one derivative, wherein (a) the concentration of (i) is higher and/or substantially the same as compared to the corresponding non-malted wheat, and (b) the concentration of (ii) is higher as compared to the corresponding non-malted wheat.
The present disclosure further relates to a consumable product produced in accordance with the herein described process, and to use of the consumable product as food or feed for humans and/or animals as well as for medical uses.
A23L 7/25 - Fermentation of cereal malt or of cereal by malting
A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
The disclosure relates to a consumable product comprising malted dehulled oat and/or a leachate of malted dehulled oat, wherein said consumable product induces endogenous production of antisecretory factor (AF) protein and/or fragments thereof in a subject after consumption. The malted dehulled oat comprised in the consumable product disclosed herein is produced by a novel malting process. The malted dehulled oat and/or a leachate of malted dehulled oat comprised in the consumable product comprises (i) avenanthramide D, wherein the concentration of (i) is higher as compared to the corresponding non-malted dehulled oats, and optionally one or more of the compounds selected from the group consisting of (ii) avenanthramide A, (iii) avenathramide C, (iv) avenanthramide C methyl ester, (v) (Z)-N-feruloyl 5- hydroxyanthranilic acid, (vi) avenanthramide G, and (vii) a compound selected from the group consisting of guaiacol or a derivative thereof, L-tryptophan, DL-phenylalanine, and any combination thereof, wherein the concentration of one or more of (ii-vii) is higher as compared to in the corresponding non-malted dehulled oats. The disclosure further provides use of the consumable product as food or feed for humans and/or animals, as well as for medical use.
HHH)-one derivative, wherein (a) the concentration of (i) is higher and/or substantially the same as compared to the corresponding non-malted wheat, and (b) the concentration of (ii) is higher as compared to the corresponding non-malted wheat. The present disclosure further relates to a consumable product produced in accordance with the herein described process, and to use of the consumable product as food or feed for humans and/or animals as well as for medical uses.
patents
